You have 9 free searches left this month | for more free features.

relapsed indolent lymphoma

Showing 1 - 25 of 7,739

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 15, 2022

Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

Active, not recruiting
  • Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
  • Nagoya, Aichi, Japan
  • +5 more
Dec 10, 2021

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 20, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Active, not recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 4, 2022

Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)

Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • BI1206
  • Atlanta, Georgia
  • +8 more
Mar 1, 2022

Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

Completed
  • Marginal Zone Lymphoma
  • +2 more
  • Harbin, Heilongjiang, China
  • +3 more
Oct 26, 2021

Non-Hodgkin Lymphoma Trial in Boston (Blinatumomab)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Boston, Massachusetts
    Massachusetts general Hospital
Jan 31, 2021

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Nov 11, 2022

Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection,

Recruiting
  • Follicular Lymphoma and Marginal Zone Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62 Injection
  • Lenalidomide
  • Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Jun 15, 2021

Leukemia Trial in New York (therapeutic autologous lymphocytes, cyclophosphamide)

Active, not recruiting
  • Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 18, 2021

Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))

Completed
  • Lymphoma Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • Nagoya, Aichi, Japan
  • +12 more
Feb 21, 2022

Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

Active, not recruiting
  • Indolent B-cell Non-Hodgkin's Lymphoma
  • Anjo, Aichi, Japan
  • +29 more
Dec 10, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

Completed
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +11 more
Jul 20, 2021

R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

Not yet recruiting
  • R/R CD19-Positive B-Cell Malignancies
  • +2 more
  • CNTY-101
  • +2 more
  • (no location specified)
Apr 22, 2022

Leukemia, Lymphoma Trial in Seattle (rituximab, fludarabine phosphate, pixantrone dimaleate)

Withdrawn
  • Leukemia
  • Lymphoma
  • rituximab
  • +2 more
  • Seattle, Washington
    Cell Therapeutics, Incorporated
Oct 14, 2020

Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))

Completed
  • Lymphoma, Non-Hodgkin
  • Copanlisib (Aliqopa, BAY80-6946)
  • Beijing, China
    Beijing Cancer Hospital
May 17, 2021

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Trial in United States (Rituximab, ALT-803)

Terminated
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
  • Rituximab
  • ALT-803
  • Minneapolis, Minnesota
  • +3 more
Feb 11, 2021

Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma Trial in Chapel Hill (CAR.k.28, Fludarabine,

Recruiting
  • Mantle Cell Lymphoma
  • +5 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Nov 19, 2021

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Recruiting
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Aug 3, 2021

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (Idelalisib,

Completed
  • Indolent Non-Hodgkin's Lymphoma
  • +2 more
  • Huntsville, Alabama
  • +10 more
Feb 22, 2021

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022